ClinicalTrials.gg
CompletedNCT06422767Updated Jul 10, 2026Results posted

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

A Phase 1 interventional study of Bepirovirsen and Placebo in Hepatitis B, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing bepirovirsen in Hepatitis B — 3 open to participants now, 6 under way, none of them phase 3. bepirovirsen · Hepatitis B.

Enrollment
11th of 16
46 · median 103
Started
2024
with 1 other
Phase 1
5 of 16
1 open now
Registered
11th of 16
by date
Lead sponsor
15 of 16
GlaxoSmithKline

Among the 16 studies testing bepirovirsen in Hepatitis B, this one is the 11th largest by enrollment, is one of 2 that started in 2024, is one of 5 in phase 1, and was the 11th registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

3 of the 16 studies testing bepirovirsen in Hepatitis B are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About bepirovirsen

bepirovirsen: first FDA approval 2026 (HIBSAGO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing bepirovirsen in Hepatitis B, or all of them as a file.
02

Study summary

This study will evaluate the effect of a single dose of bepirovirsen on the QT interval corrected by Fridericia's formula (QTcF) as compared to placebo. The data generated will be used to model the relationship between bepirovirsen concentration and QTcF.

03

Conditions studied

  • Hepatitis B

Browse trials for

Keywords

  • Bepirovirsen
  • Cardiac Conduction
  • Electrocardiogram
  • QT interval corrected by Fridericia's formula
  • Hepatitis B virus
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 55 years of age inclusive, at the time of signing the .
  • Participants who are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, (ECG) and vital signs.
  • Body weight greater than equal to (>=) 50 Kilograms (kg) and (BMI) within the range 19-32 Kilograms per square meter (kg/m\^2) (inclusive).
  • Study will enroll both male and female participants.

    o Female participants are eligible to participate if they are not pregnant or breastfeeding and are either not of or agree to using a highly effective method of .

  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
  • History of vasculitis or presence of symptoms and signs of potential vasculitis
  • History of lymphoma, leukemia, or any except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for at least 3 years.
  • Participants with any other medical conditions which, in the judgement of the investigator and/or Medical Monitor, could jeopardize the integrity of the data derived from that participant or the safety of the participant.
  • Past, current or intended use of over-the-counter or prescription medication, including herbal medications within 7 days or 5 half-lives (whichever is longer) before dosing.
  • Current or recent use of creatine-containing supplements, or intended use up to 50 days post-dosing.
  • Prior treatment with any oligonucleotide or small interfering Ribonucleic acid (RNA) (siRNA) within 12 months before dosing.
  • Exposure to more than 4 new chemical entities within 12 months before the first dosing day
  • Current enrollment or past participation in another study in which an investigational intervention (e.g., drug, vaccine, invasive device) was administered within 5 half-lives (if known) or twice the duration of biological effect (if known), whichever is longer, or within the last 90 days (if half-life and duration of biological effect are unknown), before signing of consent in any other clinical study involving an investigational study intervention or any other type of medical research.
  • Current enrollment or past participation in this clinical study.
  • Positive pre-clinical drug/alcohol screen, including tetrahydrocannabinol.
  • Positive antibody test.
  • History or regular use of tobacco or nicotine-containing products within 6 months prior to screening.
  • Regular alcohol consumption within 6 months prior to screening defined as an average weekly intake of >14 units for males or females.
  • Regular use of known drugs of abuse, including tetrahydrocannabinol.
  • Sensitivity to heparin or history of heparin-induced thrombocytopenia.
  • History of sensitivity to bepirovirsen or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor contraindicates their participation.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Positive test results for surface antigen (HBsAg), antibody or hepatitis C RNA at screening or within 3 months prior to first dose of study intervention.
  • Known history of heart disease, including ischemic heart disease, cardiomyopathy, cardiac arrhythmias, clinically significant valvular disease, or hypertensive heart disease.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
46 participants (actual)

Study arms

  • Active comparator
    Bepirovirsen: Four-Dose SC Injection

    Participant received four subcutaneous (SC) injections of Bepirovirsen dose level 1 on Day 1.

    Drug: Bepirovirsen

  • Placebo comparator
    Placebo: Four SC Injections

    Participants received four matching placebo SC injections on Day 1.

    Drug: Placebo

  • Active comparator
    Bepirovirsen: Three-Dose SC Injection

    Participant received three SC injections of Bepirovirsen dose level 1 on Day 1.

    Drug: Bepirovirsen

  • Placebo comparator
    Placebo: Three SC Injections

    Participants received three matching placebo SC injections on Day 1.

    Drug: Placebo

Interventions

  • Bepirovirsen was administered.

  • DrugPlacebo

    Placebo was administered.

06

What researchers measure

Primary outcomes

  1. Placebo-corrected Change From Baseline (CFB) in QT Interval Corrected by Fridericia's Formula (QTcF) Following Administration of Bepirovirsen Supratherapeutic Single Dose

    Continuous 12-lead electrocardiogram (ECG) was captured by Holter monitor. QTcF was measured from 10 digital ECGs extracted from the continuous tracing after 10 minutes of rest in supine position. Baseline was defined as pre-dose value on Day 1. Change from Baseline (CFB) was calculated by subtracting post-dose visit value from Baseline value. Geometric mean and 90 percent (%) Confidence Interval (CI) of predicted CFB QTcF adjusted for placebo at Cmax following supratherapeutic single doses of Bepirovirsen was presented using concentration QTc (C-QTc) analysis using exposure-response modelling. This approach utilized pre-specified linear mixed effects model where CFB QTcF was dependent variable. Fixed-effect parameters included intercept, slope, influence of Baseline on intercept, treatment and nominal time from first dose. Participant was included as additive random effect on both intercept and slope terms.

    Time frame: Baseline (Pre-dose on Day 1) and Day 4

Secondary outcomes

  1. Change From Baseline in RR Interval in ECG at Indicated Timepoints

    Twelve-lead ECGs were extracted from continuous Holter monitor tracings and RR interval was measured. RR interval is the time duration between the peak of one R wave and the peak of the very next R wave on the ECG. RR interval represents the time between two consecutive heartbeats. ECGs were extracted after a 10 minute supine rest period. Baseline was defined as pre-dose value on Day 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Pre-dose on Day 1) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 27, 30, 33, 36, 48, 51, 54, 57, 60 and 72 hours post-dose

  2. Change From Baseline in QTcF Interval, PR Interval and QRS Duration at Indicated Timepoints

    Continuous 12-lead ECG was captured by Holter monitor. QTcF, PR interval and QRS duration were measured from 10 digital ECGs extracted from the continuous tracing after 10 minutes of rest in supine position. Baseline was defined as pre-dose value on Day 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

    Time frame: Baseline (Pre-dose on Day 1) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 27, 30, 33, 36, 48, 51, 54, 57, 60 and 72 hours post-dose

  3. Number of Participants With Outlier Results for Heart Rate (HR)

    Continuous 12-lead ECG was captured by Holter monitor. HR was measured from 10 digital ECGs extracted from the continuous tracing after 10 minutes of rest in supine position. Participants with HR less than (\<) 50 beats per minute (bpm) with a decrease of HR greater than (\>) 25% and HR \>100 bpm with an increase of HR \>25% were considered as outlier.

    Time frame: Up to Day 4

  4. Number of Participants With Outlier Results for Total QTcF Interval, PR Interval and QRS Duration

    Twelve-lead ECG were obtained to measure QTcF interval, PR interval and QRS duration. 12-lead ECG were recorded in a participant using an ECG machine after 10 minutes rest in the supine position. Participants with outlier results were determined if the following criteria (which were assessed separately) were met: Participant who had treatment-emergent (TE) value of QTcF\>450 and \<=480 milliseconds (ms) when not present at Baseline (new onset); TE value of QTcF\>480 and \<=500 ms when not present at Baseline (new onset); TE value of QTcF\>500 ms when not present at Baseline (new onset); increase of QTcF from Baseline of \>30 and \<=60 ms; increase of QTcF from baseline \>60 ms; Increase in PR interval from Baseline \>25% resulting in PR \>200 ms; increase in QRS duration from Baseline \>25% resulting in QRS \>120 ms.

    Time frame: Up to Day 4

  5. Number of Participants With Treatment Emergent Changes of T Wave Morphology and U-wave Presence

    Twelve-lead ECG were obtained using an ECG machine. T-wave morphology was categorized as follows: Flat T wave: T amplitude \<1 millimeter (mm) (either positive or negative) including flat isoelectric line. Notched T wave(+): Presence of notch(es) of at least 0.05 millivolt(mV) amplitude on ascending or descending arm of positive T wave. Biphasic: T wave that contains a second component with an opposite phase that is at least 0.1 mV deep (both positive/negative and negative/positive and polyphasic T waves included). T wave Inversion: T wave which normally points upward in most leads, is seen pointing downward (negative). Normal T wave(-): T amplitude that is negative, without biphasic T wave or notches. Notched T wave(-): Presence of notch(es) of at least 0.05 mV amplitude on descending or ascending arm of the negative T wave. U waves: Presence of abnormal U waves. Number of participants who had any treatment emergent changes of T wave morphology and U-wave presence have been presented.

    Time frame: Up to Day 4

  6. Plasma Concentrations of Bepirovirsen

    Blood samples were collected at the indicated time points for pharmacokinetic (PK) analysis of Bepirovirsen.

    Time frame: At 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 27, 30, 33, 36, 48, 51, 54, 57, 60 and 72 hours post-dose

  7. Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-infinity]) of Bepirovirsen

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of Bepirovirsen.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 27, 30, 33, 36, 48, 51, 54, 57, 60 and 72 hours post-dose

  8. Area Under the Concentration-time Curve From Time Zero (Pre-dose) to 24 Hours Post-dose (AUC[0-24]) of Bepirovirsen

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of Bepirovirsen.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose

  9. Maximum Plasma Concentration (Cmax) of Bepirovirsen

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of Bepirovirsen.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 27, 30, 33, 36, 48, 51, 54, 57, 60 and 72 hours post-dose

  10. Time to Reach Cmax (Tmax) of Bepirovirsen

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of Bepirovirsen.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 27, 30, 33, 36, 48, 51, 54, 57, 60 and 72 hours post-dose

Other outcomes

  1. AUC(0-t) of Bepirovirsen

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of Bepirovirsen.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 27, 30, 33, 36, 48, 51, 54, 57, 60 and 72 hours post-dose

07

Results

Posted Jul 10, 2026

Participant flow

Participant flow — Overall Study
MilestoneBepirovirsen: Four-Dose SC InjectionPlacebo: Four SC InjectionsBepirovirsen: Three-Dose SC InjectionPlacebo: Three SC Injections
Started551818
Completed551818
Not completed0000

Outcome measures

PrimaryPlacebo-corrected Change From Baseline (CFB) in QT Interval Corrected by Fridericia's Formula (QTcF) Following Administration of Bepirovirsen Supratherapeutic Single Dose

Continuous 12-lead electrocardiogram (ECG) was captured by Holter monitor. QTcF was measured from 10 digital ECGs extracted from the continuous tracing after 10 minutes of rest in supine position. Baseline was defined as pre-dose value on Day 1. Change from Baseline (CFB) was calculated by subtracting post-dose visit value from Baseline value. Geometric mean and 90 percent (%) Confidence Interval (CI) of predicted CFB QTcF adjusted for placebo at Cmax following supratherapeutic single doses of Bepirovirsen was presented using concentration QTc (C-QTc) analysis using exposure-response modelling. This approach utilized pre-specified linear mixed effects model where CFB QTcF was dependent variable. Fixed-effect parameters included intercept, slope, influence of Baseline on intercept, treatment and nominal time from first dose. Participant was included as additive random effect on both intercept and slope terms.

Time frame:
Baseline (Pre-dose on Day 1) and Day 4
Reported as:
Geometric mean · Milliseconds
Placebo-corrected Change From Baseline (CFB) in QT Interval Corrected by Fridericia's Formula (QTcF) Following Administration of Bepirovirsen Supratherapeutic Single Dose
MillisecondsBepirovirsen: Four-Dose SC InjectionBepirovirsen: Three-Dose SC Injection
Placebo-corrected Change From Baseline (CFB) in QT Interval Corrected by Fridericia's Formula (QTcF) Following Administration of Bepirovirsen Supratherapeutic Single Dose2.360 (-0.249 to 4.970)2.024 (-0.541 to 4.589)
SecondaryChange From Baseline in RR Interval in ECG at Indicated Timepoints

Twelve-lead ECGs were extracted from continuous Holter monitor tracings and RR interval was measured. RR interval is the time duration between the peak of one R wave and the peak of the very next R wave on the ECG. RR interval represents the time between two consecutive heartbeats. ECGs were extracted after a 10 minute supine rest period. Baseline was defined as pre-dose value on Day 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Pre-dose on Day 1) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 27, 30, 33, 36, 48, 51, 54, 57, 60 and 72 hours post-dose
Reported as:
Least squares mean · Milliseconds
Change From Baseline in RR Interval in ECG at Indicated Timepoints
MillisecondsBepirovirsen: Four-Dose SC InjectionPlacebo: Four SC InjectionsBepirovirsen: Three-Dose SC InjectionPlacebo: Three SC Injections
0.5 hour-7.95 (-60.63 to 44.73)14.72 (-38.17 to 67.61)19.13 (-8.63 to 46.89)-0.93 (-28.74 to 26.87)
1 hour3.67 (-53.42 to 60.75)50.71 (-6.57 to 107.99)18.03 (-12.06 to 48.11)9.71 (-20.42 to 39.83)
1.5 hours39.14 (-11.08 to 89.37)56.68 (6.23 to 107.13)44.65 (18.18 to 71.12)20.93 (-5.59 to 47.44)
2 hours43.01 (-17.20 to 103.21)76.33 (15.94 to 136.72)16.36 (-15.37 to 48.09)-23.26 (-55.03 to 8.50)
3 hours16.12 (-44.35 to 76.58)14.63 (-46.03 to 75.28)24.20 (-7.67 to 56.07)41.34 (9.44 to 73.25)
4 hours40.29 (-20.16 to 100.74)20.71 (-39.92 to 81.35)8.19 (-23.67 to 40.05)7.28 (-24.61 to 39.18)
6 hours-120.71 (-184.84 to -56.58)-103.76 (-168.07 to -39.45)-99.72 (-133.52 to -65.91)-90.71 (-124.55 to -56.88)
8 hours-107.52 (-175.79 to -39.25)-61.77 (-130.20 to 6.66)-47.28 (-83.26 to -11.30)-12.65 (-48.66 to 23.37)
12 hours-156.23 (-221.65 to -90.81)-30.05 (-95.63 to 35.54)-94.03 (-128.50 to -59.55)-14.46 (-48.97 to 20.06)
24 hours-210.04 (-294.47 to -125.60)54.73 (-29.99 to 139.46)-174.72 (-219.22 to -130.22)-13.12 (-57.68 to 31.44)
27 hours-215.57 (-295.41 to -135.73)14.16 (-65.98 to 94.31)-235.20 (-277.28 to -193.13)-59.80 (-101.94 to -17.66)
30 hours-268.76 (-339.80 to -197.71)-75.22 (-146.61 to -3.83)-252.77 (-290.22 to -215.33)-67.37 (-104.88 to -29.86)
33 hours-309.66 (-407.15 to -212.17)0.43 (-97.32 to 98.17)-228.07 (-279.46 to -176.69)-5.83 (-57.26 to 45.60)
36 hours-277.56 (-358.50 to -196.61)-33.61 (-114.86 to 47.64)-216.23 (-258.89 to -173.57)-53.15 (-95.87 to -10.42)
48 hours-159.48 (-228.56 to -90.41)-20.07 (-89.45 to 49.31)-92.84 (-129.57 to -56.12)-33.32 (-69.76 to 3.12)
51 hours-149.11 (-211.30 to -86.91)-74.51 (-132.04 to -16.98)-95.92 (-126.04 to -65.79)-75.97 (-106.13 to -45.80)
54 hours-132.04 (-194.49 to -69.58)-75.43 (-136.06 to -14.79)-146.19 (-177.96 to -114.42)-70.96 (-102.77 to -39.15)
57 hours-128.59 (-207.53 to -49.64)-54.79 (-134.01 to 24.42)-86.77 (-128.38 to -45.16)-17.29 (-58.93 to 24.35)
60 hours-150.79 (-211.22 to -90.36)-92.73 (-153.51 to -31.94)-110.61 (-142.47 to -78.76)-92.98 (-124.87 to -61.09)
72 hours-29.90 (-95.84 to 36.04)-36.70 (-103.20 to 29.80)-70.02 (-105.79 to -34.26)-70.07 (-104.89 to -35.26)
SecondaryChange From Baseline in QTcF Interval, PR Interval and QRS Duration at Indicated Timepoints

Continuous 12-lead ECG was captured by Holter monitor. QTcF, PR interval and QRS duration were measured from 10 digital ECGs extracted from the continuous tracing after 10 minutes of rest in supine position. Baseline was defined as pre-dose value on Day 1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.

Time frame:
Baseline (Pre-dose on Day 1) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 27, 30, 33, 36, 48, 51, 54, 57, 60 and 72 hours post-dose
Reported as:
Least squares mean · Milliseconds
Change From Baseline in QTcF Interval, PR Interval and QRS Duration at Indicated Timepoints
MillisecondsBepirovirsen: Four-Dose SC InjectionPlacebo: Four SC InjectionsBepirovirsen: Three-Dose SC InjectionPlacebo: Three SC Injections
QTcF Interval, 0.5 hour-2.75 (-6.22 to 0.71)-1.80 (-5.25 to 1.65)-0.84 (-2.69 to 1.01)-3.00 (-4.84 to -1.16)
QTcF Interval, 1 hour-0.99 (-4.04 to 2.06)-1.85 (-4.89 to 1.18)-0.87 (-2.51 to 0.76)-3.85 (-5.47 to -2.22)
QTcF Interval, 1.5 hours0.03 (-4.10 to 4.17)-0.94 (-5.06 to 3.18)0.14 (-2.06 to 2.34)-2.19 (-4.38 to 0.00)
QTcF Interval, 2 hours1.09 (-2.02 to 4.19)-0.95 (-4.05 to 2.14)-0.15 (-1.82 to 1.51)-3.75 (-5.41 to -2.10)
QTcF Interval, 3 hours-1.92 (-5.77 to 1.94)3.44 (-0.41 to 7.28)-0.30 (-2.36 to 1.75)-4.04 (-6.08 to -1.99)
QTcF Interval, 4 hours-1.25 (-5.57 to 3.08)2.93 (-1.39 to 7.24)0.25 (-2.05 to 2.55)-2.57 (-4.87 to -0.28)
QTcF Interval, 6 hours-5.97 (-11.62 to -0.33)-3.67 (-9.31 to 1.97)-9.00 (-11.99 to -6.01)-9.68 (-12.67 to -6.70)
QTcF Interval, 8 hours-7.22 (-12.81 to -1.63)-2.42 (-8.00 to 3.16)-8.68 (-11.64 to -5.72)-10.65 (-13.61 to -7.70)
QTcF Interval, 12 hours-6.19 (-12.49 to 0.11)-1.19 (-7.49 to 5.10)-10.16 (-13.49 to -6.82)-9.25 (-12.58 to -5.93)
QTcF Interval, 24 hours-10.46 (-16.96 to -3.96)0.99 (-5.47 to 7.45)-14.35 (-17.85 to -10.85)-10.12 (-13.58 to -6.65)
QTcF Interval, 27 hours-15.45 (-24.33 to -6.57)-5.24 (-14.09 to 3.62)-17.87 (-22.60 to -13.13)-10.81 (-15.52 to -6.10)
QTcF Interval, 30 hours-15.92 (-24.91 to -6.92)-1.10 (-10.07 to 7.87)-16.62 (-21.41 to -11.83)-9.23 (-14.00 to -4.45)
QTcF Interval, 33 hours-15.32 (-23.62 to -7.02)-1.35 (-9.62 to 6.92)-8.72 (-13.15 to -4.29)-3.01 (-7.42 to 1.40)
QTcF Interval, 36 hours-10.69 (-18.14 to -3.25)-2.31 (-9.72 to 5.11)-10.65 (-14.63 to -6.66)-5.38 (-9.34 to -1.41)
QTcF Interval, 48 hours-5.10 (-11.25 to 1.05)2.26 (-3.86 to 8.38)-3.69 (-7.02 to -0.36)-6.20 (-9.47 to -2.93)
QTcF Interval, 51 hours-9.06 (-15.38 to -2.74)-6.68 (-12.30 to -1.05)-7.48 (-10.52 to -4.44)-11.75 (-14.77 to -8.74)
QTcF Interval, 54 hours-4.72 (-10.72 to 1.28)-2.33 (-8.06 to 3.40)-9.56 (-12.65 to -6.46)-11.74 (-14.81 to -8.67)
QTcF Interval, 57 hours-6.08 (-12.97 to 0.81)0.25 (-6.62 to 7.11)-4.65 (-8.33 to -0.97)-5.95 (-9.61 to -2.29)
QTcF Interval, 60 hours-11.87 (-17.97 to -5.78)-1.28 (-7.35 to 4.79)-7.83 (-11.10 to -4.56)-7.81 (-11.06 to -4.56)
QTcF Interval, 72 hours-1.43 (-7.18 to 4.31)1.50 (-4.19 to 7.20)-5.20 (-8.43 to -1.98)-7.64 (-10.72 to -4.55)
PR Interval, 0.5 hour-1.94 (-5.10 to 1.23)-1.17 (-4.31 to 1.96)0.57 (-1.07 to 2.22)0.00 (-1.65 to 1.65)
PR Interval, 1 hour0.20 (-3.27 to 3.66)4.96 (1.52 to 8.40)1.67 (-0.14 to 3.48)-0.59 (-2.41 to 1.22)
PR Interval, 1.5 hours-0.00 (-3.39 to 3.39)-3.49 (-6.85 to -0.12)0.75 (-1.02 to 2.52)-0.07 (-1.85 to 1.70)
PR Interval, 2 hours-0.80 (-4.00 to 2.40)-1.77 (-4.94 to 1.39)0.52 (-1.15 to 2.18)-0.83 (-2.50 to 0.84)
PR Interval, 3 hours-2.34 (-6.86 to 2.18)-1.33 (-5.83 to 3.17)0.39 (-1.98 to 2.76)0.11 (-2.26 to 2.49)
PR Interval, 4 hours2.73 (-2.27 to 7.74)3.63 (-1.35 to 8.62)-0.45 (-3.07 to 2.18)-0.29 (-2.92 to 2.33)
PR Interval, 6 hours-1.80 (-6.09 to 2.48)-4.24 (-8.50 to 0.02)-3.34 (-5.59 to -1.10)-2.44 (-4.69 to -0.19)
PR Interval, 8 hours-5.47 (-10.49 to -0.45)-3.41 (-8.41 to 1.60)-7.85 (-10.49 to -5.22)-4.54 (-7.17 to -1.90)
PR Interval, 12 hours-1.67 (-6.33 to 2.99)-2.57 (-7.22 to 2.07)-2.18 (-4.62 to 0.27)-0.46 (-2.91 to 1.99)
PR Interval, 24 hours-0.40 (-5.36 to 4.56)2.15 (-2.75 to 7.05)-3.58 (-6.16 to -1.01)0.99 (-1.60 to 3.58)
PR Interval, 27 hours-3.93 (-8.69 to 0.82)-4.18 (-8.88 to 0.52)-4.65 (-7.12 to -2.18)-0.22 (-2.70 to 2.26)
PR Interval, 30 hours-3.64 (-9.16 to 1.88)-4.58 (-10.05 to 0.89)-3.85 (-6.72 to -0.97)-1.75 (-4.64 to 1.13)
PR Interval, 33 hours-0.69 (-6.17 to 4.79)-2.31 (-7.74 to 3.11)-5.69 (-8.54 to -2.83)0.72 (-2.15 to 3.58)
PR Interval, 36 hours-3.60 (-10.13 to 2.93)-1.71 (-8.20 to 4.78)-3.07 (-6.48 to 0.35)0.97 (-2.45 to 4.39)
PR Interval, 48 hours-0.84 (-4.96 to 3.29)0.04 (-4.03 to 4.12)-0.29 (-2.48 to 1.89)0.34 (-1.81 to 2.49)
PR Interval, 51 hours6.31 (1.79 to 10.84)-2.49 (-6.30 to 1.31)-1.33 (-3.33 to 0.67)-1.50 (-3.51 to 0.51)
PR Interval, 54 hours0.34 (-3.95 to 4.64)-5.69 (-9.68 to -1.70)-3.89 (-5.99 to -1.79)-2.53 (-4.64 to -0.42)
PR Interval, 57 hours-1.37 (-5.83 to 3.10)-2.16 (-6.58 to 2.26)-2.66 (-4.99 to -0.34)-0.52 (-2.85 to 1.81)
PR Interval, 60 hours1.70 (-3.91 to 7.30)-2.20 (-7.76 to 3.37)-0.59 (-3.52 to 2.34)0.42 (-2.52 to 3.35)
PR Interval, 72 hours1.29 (-3.74 to 6.31)0.26 (-4.67 to 5.19)1.20 (-1.46 to 3.87)1.84 (-0.76 to 4.45)
QRS Duration, 0.5 hour0.09 (-0.90 to 1.09)0.21 (-0.78 to 1.20)-0.39 (-0.92 to 0.13)-0.03 (-0.55 to 0.49)
QRS Duration, 1 hour0.12 (-1.07 to 1.32)-0.06 (-1.25 to 1.13)-0.73 (-1.36 to -0.10)-0.03 (-0.66 to 0.60)
QRS Duration, 1.5 hours0.06 (-0.78 to 0.90)-0.15 (-0.98 to 0.69)0.17 (-0.27 to 0.61)-0.20 (-0.64 to 0.24)
QRS Duration, 2 hours-0.28 (-1.28 to 0.73)-0.19 (-1.19 to 0.81)0.40 (-0.13 to 0.93)-0.11 (-0.63 to 0.42)
QRS Duration, 3 hours-0.74 (-1.60 to 0.11)0.44 (-0.41 to 1.29)-0.33 (-0.77 to 0.12)-0.24 (-0.68 to 0.21)
QRS Duration, 4 hours-0.68 (-2.07 to 0.72)0.72 (-0.68 to 2.11)-0.31 (-1.05 to 0.42)0.53 (-0.20 to 1.27)
QRS Duration, 6 hours-0.54 (-1.54 to 0.45)0.21 (-0.78 to 1.20)-0.27 (-0.79 to 0.26)-0.37 (-0.89 to 0.15)
QRS Duration, 8 hours-0.01 (-1.21 to 1.19)1.61 (0.42 to 2.80)0.16 (-0.47 to 0.79)-0.70 (-1.33 to -0.07)
QRS Duration, 12 hours-0.74 (-1.94 to 0.45)0.81 (-0.38 to 2.00)0.02 (-0.61 to 0.65)-0.33 (-0.96 to 0.30)
QRS Duration, 24 hours-1.08 (-2.34 to 0.18)-0.25 (-1.50 to 0.99)0.09 (-0.58 to 0.75)0.11 (-0.54 to 0.77)
QRS Duration, 27 hours-1.15 (-2.45 to 0.15)0.55 (-0.74 to 1.84)-0.18 (-0.86 to 0.51)-0.73 (-1.41 to -0.05)
QRS Duration, 30 hours-0.38 (-1.87 to 1.11)0.55 (-0.93 to 2.02)0.05 (-0.73 to 0.84)-1.24 (-2.02 to -0.46)
QRS Duration, 33 hours-1.22 (-2.73 to 0.29)1.35 (-0.15 to 2.84)0.63 (-0.17 to 1.42)-0.51 (-1.31 to 0.28)
QRS Duration, 36 hours-1.48 (-3.18 to 0.21)-0.25 (-1.94 to 1.43)0.34 (-0.55 to 1.23)-0.15 (-1.04 to 0.73)
QRS Duration, 48 hours-0.97 (-2.57 to 0.63)-0.18 (-1.77 to 1.40)0.46 (-0.40 to 1.31)-0.19 (-1.02 to 0.65)
QRS Duration, 51 hours-1.13 (-2.71 to 0.45)0.02 (-1.38 to 1.41)0.56 (-0.18 to 1.30)-0.04 (-0.78 to 0.70)
QRS Duration, 54 hours-1.51 (-3.14 to 0.12)0.08 (-1.46 to 1.62)0.50 (-0.31 to 1.32)-0.98 (-1.80 to -0.17)
QRS Duration, 57 hours0.16 (-1.19 to 1.51)1.15 (-0.19 to 2.49)0.84 (0.13 to 1.55)0.35 (-0.35 to 1.06)
QRS Duration, 60 hours0.43 (-1.18 to 2.03)0.96 (-0.63 to 2.55)0.75 (-0.10 to 1.59)-0.02 (-0.86 to 0.82)
QRS Duration, 72 hours-0.50 (-2.89 to 1.88)0.42 (-1.92 to 2.77)0.44 (-0.85 to 1.73)0.34 (-0.90 to 1.58)
SecondaryNumber of Participants With Outlier Results for Heart Rate (HR)

Continuous 12-lead ECG was captured by Holter monitor. HR was measured from 10 digital ECGs extracted from the continuous tracing after 10 minutes of rest in supine position. Participants with HR less than (\<) 50 beats per minute (bpm) with a decrease of HR greater than (\>) 25% and HR \>100 bpm with an increase of HR \>25% were considered as outlier.

Time frame:
Up to Day 4
Reported as:
Count of participants · Participants
Number of Participants With Outlier Results for Heart Rate (HR)
ParticipantsBepirovirsen: Four-Dose SC InjectionPlacebo: Four SC InjectionsBepirovirsen: Three-Dose SC InjectionPlacebo: Three SC Injections
HR <50 bpm with a decrease of HR >25%0000
HR >100 bpm with an increase of HR >25%3080
SecondaryNumber of Participants With Outlier Results for Total QTcF Interval, PR Interval and QRS Duration

Twelve-lead ECG were obtained to measure QTcF interval, PR interval and QRS duration. 12-lead ECG were recorded in a participant using an ECG machine after 10 minutes rest in the supine position. Participants with outlier results were determined if the following criteria (which were assessed separately) were met: Participant who had treatment-emergent (TE) value of QTcF\>450 and \<=480 milliseconds (ms) when not present at Baseline (new onset); TE value of QTcF\>480 and \<=500 ms when not present at Baseline (new onset); TE value of QTcF\>500 ms when not present at Baseline (new onset); increase of QTcF from Baseline of \>30 and \<=60 ms; increase of QTcF from baseline \>60 ms; Increase in PR interval from Baseline \>25% resulting in PR \>200 ms; increase in QRS duration from Baseline \>25% resulting in QRS \>120 ms.

Time frame:
Up to Day 4
Reported as:
Count of participants · Participants
Number of Participants With Outlier Results for Total QTcF Interval, PR Interval and QRS Duration
ParticipantsBepirovirsen: Four-Dose SC InjectionPlacebo: Four SC InjectionsBepirovirsen: Three-Dose SC InjectionPlacebo: Three SC Injections
Total QTcF interval0000
Total PR interval0000
Total QRS duration0000
SecondaryNumber of Participants With Treatment Emergent Changes of T Wave Morphology and U-wave Presence

Twelve-lead ECG were obtained using an ECG machine. T-wave morphology was categorized as follows: Flat T wave: T amplitude \<1 millimeter (mm) (either positive or negative) including flat isoelectric line. Notched T wave(+): Presence of notch(es) of at least 0.05 millivolt(mV) amplitude on ascending or descending arm of positive T wave. Biphasic: T wave that contains a second component with an opposite phase that is at least 0.1 mV deep (both positive/negative and negative/positive and polyphasic T waves included). T wave Inversion: T wave which normally points upward in most leads, is seen pointing downward (negative). Normal T wave(-): T amplitude that is negative, without biphasic T wave or notches. Notched T wave(-): Presence of notch(es) of at least 0.05 mV amplitude on descending or ascending arm of the negative T wave. U waves: Presence of abnormal U waves. Number of participants who had any treatment emergent changes of T wave morphology and U-wave presence have been presented.

Time frame:
Up to Day 4
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Changes of T Wave Morphology and U-wave Presence
ParticipantsBepirovirsen: Four-Dose SC InjectionPlacebo: Four SC InjectionsBepirovirsen: Three-Dose SC InjectionPlacebo: Three SC Injections
Flat T wave0100
Notched T wave (+)0000
Biphasic0000
T wave Inversion0020
Normal T wave (-)0000
Notched T wave (-)0000
U waves0000
SecondaryPlasma Concentrations of Bepirovirsen

Blood samples were collected at the indicated time points for pharmacokinetic (PK) analysis of Bepirovirsen.

Time frame:
At 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 27, 30, 33, 36, 48, 51, 54, 57, 60 and 72 hours post-dose
Reported as:
Mean · Nanogram per milliliter (ng/mL)
Plasma Concentrations of Bepirovirsen
Nanogram per milliliter (ng/mL)Bepirovirsen: Four-Dose SC InjectionBepirovirsen: Three-Dose SC Injection
0.5 HOUR POST DOSE4200.000 (1646.754 to 6753.246)4609.529 (964.519 to 8254.539)
1 HOUR POST DOSE9054.000 (4466.537 to 13641.463)7749.444 (5084.232 to 10414.657)
1.5 HOURS POST DOSE12842.000 (6817.104 to 18866.896)10185.294 (8036.832 to 12333.756)
2 HOURS POST DOSE14048.000 (9182.574 to 18913.426)12137.500 (10047.899 to 14227.101)
3 HOURS POST DOSE16152.000 (10647.167 to 21656.833)14115.882 (12298.053 to 15933.712)
4 HOURS POST DOSE16696.000 (11867.748 to 21524.252)15061.111 (13733.795 to 16388.428)
6 HOURS POST DOSE15210.000 (9582.530 to 20837.470)13112.778 (11896.945 to 14328.610)
8 HOURS POST DOSE12580.000 (9399.759 to 15760.241)11667.222 (10398.191 to 12936.254)
12 HOURS POST DOSE11438.000 (7101.673 to 15774.327)8303.750 (6989.831 to 9617.669)
24 HOURS POST DOSE1485.250 (132.388 to 2838.112)1101.286 (598.829 to 1603.743)
27 HOURS POST DOSE893.400 (543.042 to 1243.758)630.000 (359.829 to 900.171)
30 HOURS POST DOSE618.400 (444.789 to 792.011)361.612 (218.487 to 504.737)
33 HOURS POST DOSE357.600 (271.666 to 443.534)245.383 (118.524 to 372.243)
36 HOURS POST DOSE227.600 (199.113 to 256.087)160.429 (82.066 to 238.793)
48 HOURS POST DOSE84.220 (64.387 to 104.053)64.194 (35.668 to 92.721)
51 HOURS POST DOSE70.060 (50.720 to 89.400)46.100 (30.050 to 62.150)
54 HOURS POST DOSE62.960 (44.833 to 81.087)33.833 (24.425 to 43.242)
57 HOURS POST DOSE49.800 (33.689 to 65.911)29.844 (23.858 to 35.831)
60 HOURS POST DOSE44.300 (30.819 to 57.781)25.978 (21.367 to 30.588)
72 HOURS POST DOSE32.500 (21.637 to 43.363)20.344 (17.238 to 23.449)
SecondaryArea Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-infinity]) of Bepirovirsen

Blood samples were collected at the indicated time points for pharmacokinetic analysis of Bepirovirsen.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 27, 30, 33, 36, 48, 51, 54, 57, 60 and 72 hours post-dose
Reported as:
Geometric mean · Hour*Microgram per milliliter (h*ug/mL)
Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-infinity]) of Bepirovirsen
Hour*Microgram per milliliter (h*ug/mL)Bepirovirsen: Four-Dose SC InjectionBepirovirsen: Three-Dose SC Injection
Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-infinity]) of BepirovirsenNA ± NANA ± NA
SecondaryArea Under the Concentration-time Curve From Time Zero (Pre-dose) to 24 Hours Post-dose (AUC[0-24]) of Bepirovirsen

Blood samples were collected at the indicated time points for pharmacokinetic analysis of Bepirovirsen.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose
Reported as:
Geometric mean · Hour*Microgram per milliliter (h*ug/mL)
Area Under the Concentration-time Curve From Time Zero (Pre-dose) to 24 Hours Post-dose (AUC[0-24]) of Bepirovirsen
Hour*Microgram per milliliter (h*ug/mL)Bepirovirsen: Four-Dose SC InjectionBepirovirsen: Three-Dose SC Injection
Area Under the Concentration-time Curve From Time Zero (Pre-dose) to 24 Hours Post-dose (AUC[0-24]) of Bepirovirsen204.01 ± 31.68169.80 ± 24.88
SecondaryMaximum Plasma Concentration (Cmax) of Bepirovirsen

Blood samples were collected at the indicated time points for pharmacokinetic analysis of Bepirovirsen.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 27, 30, 33, 36, 48, 51, 54, 57, 60 and 72 hours post-dose
Reported as:
Geometric mean · Microgram per milliliter (ug/mL)
Maximum Plasma Concentration (Cmax) of Bepirovirsen
Microgram per milliliter (ug/mL)Bepirovirsen: Four-Dose SC InjectionBepirovirsen: Three-Dose SC Injection
Maximum Plasma Concentration (Cmax) of Bepirovirsen16.88 ± 43.0715.77 ± 29.61
SecondaryTime to Reach Cmax (Tmax) of Bepirovirsen

Blood samples were collected at the indicated time points for pharmacokinetic analysis of Bepirovirsen.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 27, 30, 33, 36, 48, 51, 54, 57, 60 and 72 hours post-dose
Reported as:
Geometric mean · Hour (h)
Time to Reach Cmax (Tmax) of Bepirovirsen
Hour (h)Bepirovirsen: Four-Dose SC InjectionBepirovirsen: Three-Dose SC Injection
Time to Reach Cmax (Tmax) of Bepirovirsen4.10 ± 25.103.38 ± 56.88
Other pre-specifiedAUC(0-t) of Bepirovirsen

Blood samples were collected at the indicated time points for pharmacokinetic analysis of Bepirovirsen.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 27, 30, 33, 36, 48, 51, 54, 57, 60 and 72 hours post-dose
Reported as:
Geometric mean · Hour*microgram per milliliter (h*ug/mL)
AUC(0-t) of Bepirovirsen
Hour*microgram per milliliter (h*ug/mL)Bepirovirsen: Four-Dose SC InjectionBepirovirsen: Three-Dose SC Injection
AUC(0-t) of Bepirovirsen215.04 ± 30.26177.21 ± 24.39

Adverse events

Collected over All-cause mortality, serious adverse events (SAEs) and non-serious adverse events (non-SAEs) were collected up to Day 50. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bepirovirsen: Four-Dose SC Injection0/5 (0%)0/5 (0%)5/5 (100%)
Placebo: Four SC Injections0/5 (0%)0/5 (0%)1/5 (20%)
Bepirovirsen: Three-Dose SC Injection0/18 (0%)0/18 (0%)15/18 (83.3%)
Placebo: Three SC Injections0/18 (0%)0/18 (0%)2/18 (11.1%)
Most frequent other events
Showing 10 of 31
Most frequent other events
EventBepirovirsen: Four-Dose SC InjectionPlacebo: Four SC InjectionsBepirovirsen: Three-Dose SC InjectionPlacebo: Three SC Injections
Injection site erythemaGeneral disorders5/50/514/180/18
Injection site discolourationGeneral disorders4/50/51/180/18
Injection site swellingGeneral disorders4/50/513/180/18
NauseaGastrointestinal disorders3/50/53/180/18
Injection site painGeneral disorders3/50/59/180/18
HeadacheNervous system disorders3/50/55/181/18
Injection site pruritusGeneral disorders2/50/52/180/18
MyalgiaMusculoskeletal and connective tissue disorders2/50/52/180/18
Injection site bruisingGeneral disorders1/50/55/180/18
PyrexiaGeneral disorders0/50/54/180/18

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Bepirovirsen: Four-Dose SC InjectionPlacebo: Four SC InjectionsBepirovirsen: Three-Dose SC InjectionPlacebo: Three SC InjectionsTotal
Mean31.4 ± 11.2433.2 ± 4.0239.4 ± 7.9638.6 ± 10.2937.5 ± 9.20
Sex: Female, Male
Sex: Female, Male(Participants)Bepirovirsen: Four-Dose SC InjectionPlacebo: Four SC InjectionsBepirovirsen: Three-Dose SC InjectionPlacebo: Three SC InjectionsTotal
Female3210419
Male2381427
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bepirovirsen: Four-Dose SC InjectionPlacebo: Four SC InjectionsBepirovirsen: Three-Dose SC InjectionPlacebo: Three SC InjectionsTotal
AMERICAN INDIAN OR ALASKA NATIVE00112
BLACK OR AFRICAN AMERICAN135615
MULTIPLE10001
WHITE32121128
08

Study locations

1 site
  • GSK Investigational Site
    Austin, Texas 78744 -1645, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Apr 2025, 9 months.

Results were first posted in Jul 2026, 1 year 2 months after primary completion.

Of 49 industry-sponsored phase 1 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 9 months is below that.

Counting every sponsor, half of 58 studies reached it within 14 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2024
First posted
May 21, 2024
StartActual
Jul 18, 2024
Primary completionActual
Apr 28, 2025
CompletionActual
Apr 28, 2025
Results first posted
Jul 10, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06422767
Lead sponsor
GlaxoSmithKline
Collaborators
PPD Development, LP
Responsible party
Sponsor
First posted
May 21, 2024
Start date
Jul 18, 2024
Primary completion
Apr 28, 2025
Completion
Apr 28, 2025
Results posted
Jul 10, 2026
Last update
Jul 10, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bepirovirsen

Start the discussion